Processa Pharmaceuticals, Inc.
As of Oct 22, 2026, Processa Pharmaceuticals is in Stage 4, the downtrend phase, now in week 19 (since Jun 9, 2026). It closed at $1.86, 80.9% below its 52-week high and below its 200-day average, which is falling.
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is PCSA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
PCSA among Biotechnology447th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …447 | PCSA | Stage 4 · wk 19 | 13 | −1.6% |
Processa Pharmaceuticals: quick answers
What stage is Processa Pharmaceuticals in?
As of Oct 22, 2026, Processa Pharmaceuticals (PCSA) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 9, 2026 and is in week 19. What the four stages mean
Is Processa Pharmaceuticals in an uptrend?
No. Processa Pharmaceuticals is in a Stage 4 downtrend. It trades 22.7% below its 200-day average, which is falling.
How far is Processa Pharmaceuticals from its 52-week high?
Processa Pharmaceuticals closed at $1.86 on Oct 22, 2026, 80.9% below its 52-week high of $9.73. Its 52-week low is $1.35.
How has Processa Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Processa Pharmaceuticals is down 75.2% over the past year and down 36.5% so far in 2026.
Which sector and industry is Processa Pharmaceuticals in?
Processa Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.